课题基金 / 基金详情

HIV-1 vaccine-elicited antibodies target envelope glycans

HIV-1 vaccine-elicited antibodies target envelope glycans
HIV-1 疫苗引发的抗体靶向包膜聚糖
批准号:
9089881
负责人:
KEVIN O SAUNDERS
金额:
$78.02万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-06-15 至 2020-05-31

项目摘要

项目成果

KEVIN O SAUNDERS的其他基金

相似基金

相关文献

中文摘要
翻译

英文摘要
 DESCRIPTION (provided by applicant): The human immunodeficiency virus type 1 (HIV-1) pandemic continues to spread in the absence of a preventative vaccine. Broadly neutralizing antibodies (bnAbs) against HIV-1 can prevent infection of nonhuman primates, but have thus far not been elicited by vaccination. The HIV-1 envelope is covered by a dense array of host glycans that, if recognized by vaccine-induced antibodies, could generate bnAbs. BnAbs with these specificities arise in natural infection. However, to date, vaccine strategies for eliciting anti-Env glycan antibodies have shown glycan-dependent epitopes to be poorly immunogenic. In my studies of rhesus macaques vaccinated with a group M consensus envelope, CON-S, that contains a substantial proportion of high mannose sugars, I have identified macaque plasma antibodies that block the binding of anti-glycan bnAbs to HIV-1 Env. CON-S Env gp140-immunized macaques also possess sufficient antibody titers for detection of direct glycan binding in their plasma, and I have been successful in isolating glycan-reactive rhesus monoclonal antibodies from CON-S Env-vaccinated animals. The central hypothesis of this application is that immunization with a recombinant Env that is heavily glycosylated with high mannose glycans--similar to the glycoforms present on HIV-1 virions--can induce glycan-dependent neutralizing antibodies, a subset of which are in bnAb lineages. The objectives of this application are to define the development and anti-HIV-1 functions of these novel Env-induced plasma anti-Env glycan antibodies. Thus, in Aim 1, existing and new recombinant blood memory B cell antibodies directed to glycan-dependent HIV-1 envelope epitopes will be produced and their anti-HIV-1 activity characterized. In Aim 2, we will profile the ontogeny of vaccine-induced anti-glycan antibodies both with recombinant mAb production, computational inference of lineage members, and next-generation VHDJH sequencing. Finally, in Aim 3, we will interrogate the vaccine-induced HIV-1 Env glycan antibody repertoire in secondary lymphoid organs and mucosal tissue after immunization with antigenic, stabilized CON-S gp140 trimers. The results from these studies will be a major step forward in our effort to understand the immunogenicity of HIV-1 envelope glycans that comprise bnAb epitopes. The antibodies characterized here will provide templates for B cell lineage design of immunogens that enhance the glycan-dependent antibody lineages induced by Env vaccination in rhesus macaques and humans.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Conjugate nanoparticle platform development for HIV-1 envelope immunogens
  • 批准号:
    10541860
  • 项目类别:
  • 资助金额:
    $481.87万
  • 财政年份:
    2021
  • 负责人:
    KEVIN O SAUNDERS
  • 依托单位:
Project 1. Optimization and in vivo evaluation of HIV-1 Env trimer sortase A-conjugated nanoparticles
  • 批准号:
    10369069
  • 项目类别:
  • 资助金额:
    $113.16万
  • 财政年份:
    2021
  • 负责人:
    KEVIN O SAUNDERS
  • 依托单位:
Administrative Core
  • 批准号:
    10369068
  • 项目类别:
  • 资助金额:
    $27.69万
  • 财政年份:
    2021
  • 负责人:
    KEVIN O SAUNDERS
  • 依托单位:
Conjugate nanoparticle platform development for HIV-1 envelope immunogens
  • 批准号:
    10369067
  • 项目类别:
  • 资助金额:
    $471.96万
  • 财政年份:
    2021
  • 负责人:
    KEVIN O SAUNDERS
  • 依托单位:
海外基金